FOSTERA GOLD PCV

Indications: For the vaccination of healthy pigs 3 days of age or older against porcine circovirus 2 (PCV2).

Dosage and Administration
Shake well
Single-dose protocol: Administer a single 2-mL dose intramuscularly to healthy pigs 3 weeks of age or older.
Flexible, two-dose protocol: Also may be given as two 1-mL doses administered intramuscularly three weeks apart to pigs 3 days of age* or older.
The optimal choice of the dosing regimen, including age at time of vaccination, will depend on farm circumstances.
* Field experience with PCV2 vaccines indicates that waiting until 3 weeks of age to initiate a split-dose regimen may yield a better immune response, even though the vaccine is safe when given at a younger age.

How Effective Is It?
Fostera® Gold PCV contains PCV2a and PCV2b and has been shown to be effective for the vaccination of healthy pigs against PCV2, including PCV2 viremia, shedding of virus in feces, lymphoid colonization and lymphoid depletion.

How Does It Work?
A safe, smooth vaccine. Fostera® Gold PCV was developed with the unique and smooth MetaStim® adjuvant that stimulates both cell-mediated and antibody-based immunity with minimal post-vaccination reactions.8
Continued productivity at the finishing stage. PCV2 virus change and depressed immunity are unwanted surprises in pork production, especially at the finishing stage, risking pig health and productivity as well as farm profitability.

References
1. Firth C, Charleston MA, Duffy S, Shapiro B, Holmes EC. Insights into the Evolutionary History of an Emerging Livestock Pathogen: Porcine Circovirus 2. J Virol. 2009;83(24):12813-12821.
2. Data on file, Study Report No. B822R-US-14-325, Zoetis Inc.
3. Data on file, Study Report No. B822R-US-16-582, Zoetis Inc.
4. Data on file, Study Report No. B825R-US-16-667, Zoetis Inc.
5. Data on file, Study Report No. B822R-US-15-557, Zoetis Inc.
6. Data on file, Study Report No. B824R-US-15-451, Zoetis Inc.
7. Data on file, Study Report No. B824R-US-13-118, Zoetis Inc.
8. Data on file, Study Report No. B921R-US-16-609, Zoetis Inc.
9. Data on file, Study Report No. B921R-US-20-992, Zoetis Inc